Josep M. Llovet, MD, PhD, on Treatment Options in Hepatocellular Carcinoma
ESMO Congress 2024
Josep M. Llovet, MD, PhD, presented the results of the LEAP-012 trial during the Presidential Symposium I at the ESMO Congress 2024 (Abstract LBA3). In this brief summary, Dr. Llovet talks further about how management of hepatocellular carcinoma differs across stages.
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Dr Josep Llovet:
So hepatocellular carcinoma is a major health problem globally. Is the second cause of cancer-related death, and there are around 1 million cases globally. Around 30% of the patients are diagnosed at an earlier stage, and are potentially treated with curative therapies, resection, liver transplantation, and local ablation.
Then, 20 to 30% of the patients are diagnosed at intermediate stage. And currently the standard of care is transarterial embolization. And with the LEAP-012 study, we are proposing to switch the standard of care to lenvatinib, pembrolizumab, and TACE instead of TACE. And then, around 40 to 50% of the cases are diagnosed at advanced stages of the disease. Meaning, they have vascular invasion, lymph node involvement or extrahepatic spread, or ECOG performance status 1/2. And with these patients there have been a revolution in the management, even in the last 15 years. In front-line we have immune-based regimes, like atezolizumab plus bevacizumab, and durvalumab plus tremelimumab, and nivolumab plus ipilimumab. And for those patients that have contraindications for immune-based regimes, the current standard of care is lenvatinib or sorafenib.
In patients progressing to these lines of therapy, both regorafenib and cabozantinib, and also a monoclonal antibody, ramucirumab, have shown also to impact in survival. So this gives you a picture of the current management of the disease throughout different stages.
Related Videos
The ASCO Post Staff
Maeve Lowery, MD, discusses the results of the phase II DUBHE-H-308 trial, which evaluated QL1706—a bifunctional antibody consisting of iparomlimab and tuvonralimab—plus bevacizumab and/or chemotherapy in the first-line treatment of advanced hepatocellular carcinoma (Abstract LBA38).
The ASCO Post Staff
In light of the landmark 5-year overall survival results from HIMALAYA, Ghassan K. Abou-Alfa, MD, MBA, FASCO, of Memorial Sloan Kettering Cancer Center, New York, and Lorenza Rimassa, MD, discuss how to choose among the various doublet immunotherapy options for unresectable hepatocellular carcinoma.
For more on the HIMALAYA trial, view part 1 of this discussion.
The ASCO Post Staff
Rachna T. Shroff, MD, MS, FASCO, was the discussant for a phase III trial presented at the ESMO Congress 2024 evaluating the efficacy and safety of anlotinib plus penpulimab vs sorafenib as first-line therapy for advanced hepatocellular carcinoma (Abstract LBA40).
The ASCO Post Staff
Ghassan K. Abou-Alfa, MD, MBA, FASCO, of Memorial Sloan Kettering Cancer Center, New York, and Lorenza Rimassa, MD, of Humanitas Cancer Center, Milan, discuss the 5-year overall survival results from the phase III HIMALAYA trial evaluating tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (Abstract 947MO).
For more on the HIMALAYA trial, view part 2 of this discussion.
�
The ASCO Post Staff
Josep M. Llovet, MD, PhD, presented the results of the phase III LEAP-012 trial, which evaluated the addition of lenvatinib plus pembrolizumab to transarterial chemoembolization (TACE), during the Presidential Symposium I at the ESMO Congress 2024 (Abstract LBA3).
For more insights into the treatment of hepatocellular carcinoma, view Dr. Llovet's discussion here.